STAT | Reporting from the frontiers of health and medicine Follow STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal https://www.statnews.com/pharmalot/2026/08/18/eyepoint-blindness-treatment-setback-amylyx-avexitide-win/ statnews.com
